Twist Bioscience Corporation (NASDAQ:TWST) Stock Has Average Target Price of $141.00 According to Brokerages

Key Points

• Analyst sentiment is mixed: Twelve firms rate Twist Bioscience “Hold” overall (seven buy, three hold, two sell), with an average 12-month price target of $141. Several analysts recently lowered targets, including Baird to $135 and TD Cowen to $137.
• Recent results beat expectations: Fiscal Q4 revenue rose 26.7% year over year to $126.64 million, and the loss of $0.32 per share was narrower than forecast. Fiscal Q1 2027 revenue guidance of $130 million–$132 million also topped consensus.
• Shares traded at $111.60 on Friday. Recent CEO and CFO share sales were made to cover tax withholding on vested equity awards.

Shares of Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) have received a consensus rating of "Hold" from the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $141.00.

TWST has been the subject of a number of recent research reports. Robert W. Baird dropped their target price on Twist Bioscience from $187.00 to $135.00 and set an "outperform" rating for the company in a report on Friday. Jefferies Financial Group set a $125.00 price target on Twist Bioscience in a report on Thursday. TD Cowen lowered their price target on Twist Bioscience from $190.00 to $137.00 and set a "buy" rating for the company in a research report on Friday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a research note on Monday, September 21st. Finally, Guggenheim increased their target price on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a "buy" rating in a research note on Thursday, October 1st.

Insider Transactions at Twist Bioscience

In related news, CEO Emily Leproust sold 4,573 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total transaction of $619,184.20. Following the completion of the sale, the chief executive officer owned 558,187 shares of the company's stock, valued at $75,578,519.80. This represents a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,462 shares of the business's stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $156.30, for a total value of $384,810.60. Following the sale, the chief financial officer owned 98,114 shares in the company, valued at $15,335,218.20. The trade was a 2.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 495,279 shares of company stock valued at $80,489,387 in the last ninety days. Corporate insiders own 3.08% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Twist Bioscience in the 2nd quarter valued at $600,191,000. William Blair Investment Management LLC acquired a new position in Twist Bioscience during the second quarter worth $223,722,000. Stephens Investment Management Group LLC lifted its holdings in Twist Bioscience by 1.7% during the third quarter. Stephens Investment Management Group LLC now owns 780,419 shares of the company's stock valued at $150,808,000 after purchasing an additional 13,055 shares in the last quarter. Bank of America Corp DE purchased a new position in Twist Bioscience during the second quarter valued at $94,922,000. Finally, Russell Investments Group Ltd. grew its position in shares of Twist Bioscience by 190.8% in the third quarter. Russell Investments Group Ltd. now owns 283,910 shares of the company's stock valued at $54,863,000 after purchasing an additional 186,294 shares during the period.

More Twist Bioscience News

Here's some of the latest news about TWST:

• Positive Sentiment: Fiscal Q4 revenue rose about 27% year over year to $126.6 million, beating consensus, while the $0.32-per-share loss was narrower than analysts expected. AI drug-discovery revenue totaled $59.1 million for fiscal 2026. Article: Twist Bioscience: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Fiscal Q1 2027 revenue guidance of $130 million–$132 million is above the $126.3 million consensus estimate. Article: Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
• Negative Sentiment: Leerink Partners cut its price target to $175 from $190, TD Cowen to $137 from $190, and Baird to $135 from $187. Each maintained a positive rating—outperform or buy—but the reductions indicate more cautious valuation expectations. Leerink Partners ratings

Twist Bioscience Price Performance

Shares of TWST traded down $2.62 during trading hours on Friday, reaching $111.60. 2,046,855 shares of the stock traded hands, compared to its average volume of 2,468,840. The company has a market cap of $7.00 billion, a P/E ratio of -53.40 and a beta of 2.25. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The company's 50-day moving average price is $150.23 and its two-hundred day moving average price is $93.07. Twist Bioscience has a 52-week low of $23.30 and a 52-week high of $219.71.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.07. The company had revenue of $126.64 million for the quarter, compared to analysts' expectations of $123.55 million. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. Twist Bioscience's quarterly revenue was up 26.7% on a year-over-year basis. On average, analysts anticipate that Twist Bioscience will post -1.52 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.